PolyPid Ltd. (NASDAQ:PYPD) Shares Acquired by Rosalind Advisors Inc.

Rosalind Advisors Inc. increased its stake in shares of PolyPid Ltd. (NASDAQ:PYPD) by 50.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,022,521 shares of the company’s stock after purchasing an additional 343,353 shares during the quarter. PolyPid makes up approximately 1.6% of Rosalind Advisors Inc.’s holdings, making the stock its 19th largest holding. Rosalind Advisors Inc. owned 10.03% of PolyPid worth $3,108,000 at the end of the most recent reporting period.

Separately, Stonepine Capital Management LLC purchased a new stake in shares of PolyPid during the third quarter worth about $476,000. Institutional investors own 26.47% of the company’s stock.

Wall Street Analysts Forecast Growth

PYPD has been the topic of several recent analyst reports. Rodman & Renshaw began coverage on shares of PolyPid in a research note on Tuesday, January 28th. They set a “buy” rating and a $13.00 price objective on the stock. RODMAN&RENSHAW raised PolyPid to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, HC Wainwright decreased their price objective on PolyPid from $14.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, December 26th.

PolyPid Price Performance

PolyPid stock opened at $2.81 on Friday. PolyPid Ltd. has a 1 year low of $2.37 and a 1 year high of $5.50. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.00 and a current ratio of 1.31. The firm has a 50 day moving average price of $3.00 and a 200 day moving average price of $3.21. The company has a market cap of $28.64 million, a price-to-earnings ratio of -0.57 and a beta of 1.27.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.23). Sell-side analysts predict that PolyPid Ltd. will post -1.79 earnings per share for the current year.

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.